Steven Potwin, OD
Optometrist · Saint Albans, WVNPI 1326335282
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,375 of the $23,967 with a category attached, or 80.8%. Atlas Ocular, Inc accounts for 75.1% of it on its own, with 20 other manufacturers making up the rest. Among optometrist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $232.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atlas Ocular, Inc$18K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Rxsight Inc$1K
- Alcon$680
- Johnson & Johnson Vision Care, Inc.$465
- Sun Pharmaceutical Industries Inc.$454
- plus $2K from 15 others
What the payments were for
- Consulting fees$19,37581%
- Speaking & faculty fees$7503%
- Travel & lodging$1,5587%
- Food & beverage$2,1849%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atlas Ocular, Inc | 4 | $18,000 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $1,490 |
| Rxsight Inc | 2 | $1,023 |
| Alcon | 12 | $680 |
| Johnson & Johnson Vision Care, Inc. | 4 | $465 |
| Sun Pharmaceutical Industries Inc. | 16 | $454 |
| Coopervision Inc. | 4 | $425 |
| Bausch & Lomb Americas Inc. | 14 | $325 |
| AbbVie(2 entities) | 11 | $275 |
| Eyevance Pharmaceuticals LLC | 7 | $204 |
| Mallinckrodt Hospital Products Inc. | 4 | $185 |
| Dompe US, Inc. | 5 | $142 |
| Optovue, Inc. | 1 | $103 |
| Biotissue Holdings Inc. | 2 | $47 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $23 |
| Amgen | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| LKC Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOTRUE$1,185
- ULTRA$1,185
- RXSIGHT CONTACT LENS$1,000
- RXSIGHT INJECTOR CARTRIDGE$1,000
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,000
- LIGHT ADJUSTABLE LENS (LAL)$1,000
- RXSIGHT INJECTOR HANDPIECE$1,000
- Acuvue$375
- Biofinity Contact Lens$375
- AIR OPTIX$375
- Rocklatan$123
- Rhopressa$123
- CEQUA$122
- INFUSE$113
- OCT$103
How this compares
$23,967 in reported general payments places this provider in the 95th percentile of 210 optometrist providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 170 | $233,129 |
| XiidraLifitegrast | 50 | $64,056 |
| Cyclosporine | 42 | $34,227 |
| LumiganBimatoprost | 17 | $12,294 |
| Bromfenac Sodium | 70 | $10,795 |
| Bepotastine Besilate | 50 | $9,095 |
| Azelastine Hcl | 280 | $8,344 |
| Loteprednol Etabonate | 44 | $7,826 |
| Travoprost | 31 | $7,703 |
| Prednisolone Acetate | 109 | $5,326 |
| ProlensaBromfenac Sodium | 13 | $4,375 |
| Brimonidine Tartrate | 31 | $4,174 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 47 | $3,141 |
| Fluorometholone | 26 | $2,573 |
| Bimatoprost | 15 | $2,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $275 | $245,424187 claims |
| Bausch & Lomb Americas Inc.Xiidra | $325 | $64,05650 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $1,490 | $12,20157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 optometrist providers in West Virginia.
Other optometrist in Saint Albans
- Nathaniel StevensSaint Albans$6K
- Gregory MooreBuckhannon$28K
- Kayla CampbellBarboursville$16K
- Lee MooreCharles Town$10K
- Jill ShowalterVienna$10K
- Bryce PeekBarboursville$8K
- James FickClarksburg$8K
- Laura Suppa SammonsCharleston$8K
- Mark WhittingtonCharleston$8K
- Hobart SeeseMorgantown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.